<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Harvard Bioscience Inc — News on 6ix</title>
<link>https://6ix.com/company/harvard-bioscience-inc</link>
<description>Latest news and press releases for Harvard Bioscience Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/harvard-bioscience-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357c4a78dffbe2df0f9b27.webp</url>
<title>Harvard Bioscience Inc</title>
<link>https://6ix.com/company/harvard-bioscience-inc</link>
</image>
<item>
<title>Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-fourth-quarter-and-full-year-2025-financial-results-2</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-fourth-quarter-and-full-year-2025-financial-results-2</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed</description>
</item>
<item>
<title>Harvard Bioscience Announces Reverse Stock Split</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-reverse-stock-split-2</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-reverse-stock-split-2</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE</description>
</item>
<item>
<title>Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-to-participate-in-keybancs-virtual-healthcare-forum</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-to-participate-in-keybancs-virtual-healthcare-forum</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events an</description>
</item>
<item>
<title>Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-fourth-quarter-2025-earnings-conference-call-for-march-12-2026-at-800-am-et</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-fourth-quarter-2025-earnings-conference-call-for-march-12-2026-at-800-am-et</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the aud</description>
</item>
<item>
<title>Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-preliminary-fourth-123000752</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-preliminary-fourth-123000752</guid>
<pubDate>Tue, 10 Feb 2026 12:30:00 GMT</pubDate>
<description>Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Biosc</description>
</item>
<item>
<title>Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-strategic-consolidation-213000561</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-strategic-consolidation-213000561</guid>
<pubDate>Thu, 29 Jan 2026 21:30:00 GMT</pubDate>
<description>Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028 while improving throughput and execution HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic consolidation of its manufacturing operatio</description>
</item>
<item>
<title>Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-successful-completion-123000012</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-successful-completion-123000012</guid>
<pubDate>Wed, 17 Dec 2025 12:30:00 GMT</pubDate>
<description>Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it entered into an agreement with BroadOak Capital Partners (collectively, “BroadOak”), a life-sciences-focused inv</description>
</item>
<item>
<title>Harvard Bioscience Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-third-quarter-120000466</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-third-quarter-120000466</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by OperationsCompany Expects to Refinance or Repay the Debt in the Fourth QuarterFourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2025. “Our th</description>
</item>
<item>
<title>Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-third-quarter-120000657</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-third-quarter-120000657</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the</description>
</item>
<item>
<title>Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-expands-distribution-agreement-110000891</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-expands-distribution-agreement-110000891</guid>
<pubDate>Tue, 16 Sep 2025 11:00:00 GMT</pubDate>
<description>- Strategic expansion with trusted partner enhances customer reachHOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world’s largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific will now</description>
</item>
<item>
<title>Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-appointment-stephen-110000128</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-appointment-stephen-110000128</guid>
<pubDate>Tue, 09 Sep 2025 11:00:00 GMT</pubDate>
<description>Veteran life sciences industry financing leader appointed as new Board memberHOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board’s Nominating and Governance Committee. “We are pleased to announce Steve as the newest member of our Board of Directors at such an important</description>
</item>
<item>
<title>Harvard Bioscience Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-second-quarter-110000624</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-second-quarter-110000624</guid>
<pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
<description>Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025. “We made solid progress in the second</description>
</item>
<item>
<title>Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-second-quarter-203000857</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-second-quarter-203000857</guid>
<pubDate>Mon, 04 Aug 2025 20:30:00 GMT</pubDate>
<description>HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-</description>
</item>
<item>
<title>Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-ceo-succession-110000128</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-ceo-succession-110000128</guid>
<pubDate>Thu, 17 Jul 2025 11:00:00 GMT</pubDate>
<description>Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planne</description>
</item>
<item>
<title>Harvard Bioscience Appoints John Duke to Board of Directors</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-appoints-john-duke-205700283</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-appoints-john-duke-205700283</guid>
<pubDate>Mon, 02 Jun 2025 20:57:00 GMT</pubDate>
<description>HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. “We are pleased to welcome John to Harvard Bioscience’s board,” said Katherine Eade, Lead I</description>
</item>
<item>
<title>Harvard Bioscience Announces First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-first-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-first-quarter-2025-financial-results</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first</description>
</item>
<item>
<title>Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-first-quarter-204500513</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-schedules-first-quarter-204500513</guid>
<pubDate>Mon, 05 May 2025 20:45:00 GMT</pubDate>
<description>HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-onl</description>
</item>
<item>
<title>Harvard Bioscience Announces CFO Transition</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-cfo-transition-204500768</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-cfo-transition-204500768</guid>
<pubDate>Thu, 10 Apr 2025 20:45:00 GMT</pubDate>
<description>HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignatio</description>
</item>
<item>
<title>Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-inc-participate-two-200000464</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-inc-participate-two-200000464</guid>
<pubDate>Wed, 12 Mar 2025 20:00:00 GMT</pubDate>
<description>HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day</description>
</item>
<item>
<title>Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results</title>
<link>https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-fourth-quarter-112100022</link>
<guid isPermaLink="true">https://6ix.com/company/harvard-bioscience-inc/news/harvard-bioscience-announces-fourth-quarter-112100022</guid>
<pubDate>Wed, 12 Mar 2025 11:21:00 GMT</pubDate>
<description>HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As</description>
</item>
</channel>
</rss>